Earlier this year the Office of Fair Trading (OFT) recommended to the UK government that the PPRS should be reformed substantially. The idea is to get more 'bang for the buck' on a given budget. The question remains how prices will turn out in relation to the NICE QALY theshold? It remains to be seen if there will be price increases in drugs with relatively cheap QALYs already funded and decreases be negotiated on those with a higher cost per QALY than the threshold? More open questions such as what will be conisdered cost-effcetive etc. remain open, however for sure is that there are important changes ahead for the UK HTA scene.
No comments:
Post a Comment